Lv3
296 积分 2026-02-07 加入
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2天前
已完结
Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study
5天前
已完结
Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults
5天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
15天前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
21天前
已完结
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
1个月前
已完结
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
1个月前
已完结
MRI-PDFF≥70% Reduction Was Associated With Fibrosis Improvement With Tirzepatide: Post-Hoc Analysis of the SYNERGY-NASH Phase 2B Trial
1个月前
已关闭
皖公网安备34019202002308
